Serina Therapeutics (FRA:2BO) Institutional Ownership: 2.30% (As of Jul. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:2BO Serina Therapeutics Inc FRA:2BO
21 GF Score
Price €1.67
! 1 Warning Sign
View Full Analysis

What is Serina Therapeutics Institutional Ownership?

Serina Therapeutics FRA:2BO 21 Institutional Ownership is 2.30% as of Jul. 16, 2026. GuruFocus rates FRA:2BO with a GF Score™ of 21/100. The stock has 1 warning sign investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Serina Therapeutics's institutional ownership is 2.30%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Serina Therapeutics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Serina Therapeutics's Float Percentage Of Total Shares Outstanding is 76.67%.

Serina Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Serina Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Serina Therapeutics Institutional Ownership Chart

Serina Therapeutics Historical Data

The historical data trend for Serina Therapeutics can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 3.04 3.04 3.01 3.03 3.04 3.15 3.88 3.47 2.74 2.30
FRA:2BO
21GF Score
Serina Therapeutics Inc FRA:2BO
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Serina Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 2.30% mean?
Serina Therapeutics (FRA:2BO) has a Institutional Ownership of 2.30% as of Jul. 16, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Serina Therapeutics and its competitors.
Is Serina Therapeutics' Institutional Ownership too high?
Serina Therapeutics' current Institutional Ownership is 2.30%. Overall, Serina Therapeutics has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Serina Therapeutics' Institutional Ownership compare to NRSN and IGC?
Serina Therapeutics' Institutional Ownership of 2.30% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Serina Therapeutics and its competitors. Serina Therapeutics's current Institutional Ownership is 2.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Serina Therapeutics stock overvalued right now?
Serina Therapeutics (FRA:2BO) has a current Institutional Ownership of 2.30%. The current Institutional Ownership is 2.30%. Serina Therapeutics' overall GF Score™ is 21/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Serina Therapeutics (FRA:2BO), the current Institutional Ownership is 2.30% as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Serina Therapeutics Business Description

Other Exchanges SER:USA
Address 601 Genome Way, Suite 2001, Huntsville, AL, USA, 35806
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.
21GF Score

Get the complete analysis for FRA:2BO

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.67
Price